These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37985816)

  • 1. Biallelic variants in the synaptic vesicle glycoprotein 2 A are associated with epileptic encephalopathy.
    Al-Maawali A; Al-Murshedi F; Al-Futaisi A; Mansy A; Al-Habsi A; Girisha KM
    Eur J Hum Genet; 2024 Feb; 32(2):243-246. PubMed ID: 37985816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
    CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation.
    Dilena R; Striano P; Traverso M; Viri M; Cristofori G; Tadini L; Barbieri S; Romeo A; Zara F
    Brain Dev; 2016 Jan; 38(1):128-31. PubMed ID: 26212315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
    Ohno Y; Tokudome K
    CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
    Tokudome K; Shimizu S; Serikawa T; Ohno Y
    Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.
    Badura-Stronka M; Kuszel Ł; Wencel-Warot A; Cudnoch K; Wołyńska K; Rutkowska K; Steinborn B; Płoski R
    Epilepsy Res; 2023 Feb; 190():107101. PubMed ID: 36758444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
    Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
    Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.
    Douaud M; Feve K; Pituello F; Gourichon D; Boitard S; Leguern E; Coquerelle G; Vieaud A; Batini C; Naquet R; Vignal A; Tixier-Boichard M; Pitel F
    PLoS One; 2011; 6(10):e26932. PubMed ID: 22046416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in synaptic mechanism in epileptogenesis].
    Xiao X; Ouyang Y; Song Z; Zheng W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 43(1):90-94. PubMed ID: 30154297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
    Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C
    J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A
    Calame DG; Herman I; Riviello JJ
    Epilepsy Behav Rep; 2021; 15():100425. PubMed ID: 33554103
    [No Abstract]   [Full Text] [Related]  

  • 19. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biallelic CACNA1A variants: Review of literature and report of a child with drug-resistant epilepsy and developmental delay.
    Wong-Spracklen VMY; Kolesnik A; Eck J; Sabanathan S; Spasic-Boskovic O; Maw A; Baker K
    Am J Med Genet A; 2022 Nov; 188(11):3306-3311. PubMed ID: 36063114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.